VELCADE,Rituximab,Cyclophosphamide and Decadron
VELCADE,Rituximab,Cyclophosphamide and Decadron
Overall response rate and Time to disease progression using this regimen in patients with
 low-grade B-Cell Non-Hodgkin's Lymphoma.
This is a phase II open label study that is looking at the VRCD combination regimen in
 patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by
 combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab.
 Chemotherapy cycles will be given as outlined below every 35-days and will continue until two
 cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression,
 or a maximum of 8 cycles.
Inclusion Criteria:

 -  Small Lymphocytic Lymphoma

 -  Follicular Cell Lymphoma (grades I and II)

 -  Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy
 and stem cell transplant

 -  Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia

 -  Marginal Zone Lymphoma

 -  MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.

 -  Adequate bone marrow function, renal function, and hepatic function as outlined in
 details below.

 -  ECOG performance status of 0, 1, or 2

 -  Able to read, understand, and sign an IRB approved informed consent

 Exclusion Criteria:

 -  Known HIV positive status

 -  Known CNS involvement

 -  Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.